Geopolitical Disruption in the Middle East

5 August 2026

There is no material change to the current situation. However, NHS Supply Chain has strengthened its proactive, intelligence-led approach to managing emerging risks across the supply chain.

As the situation remains dynamic, our focus is on safeguarding patient care and service delivery through early insight, targeted supplier engagement and strengthened risk controls.

What’s new in this update:

Additional information on shipping route disruption risks and potential impacts on product lead times and costs.

Previously introduced measures continue to include:

Introduction of a Middle East product risk watchlist to track products reliant on petrochemical-based materials.
Enhanced monitoring of raw material impacts in key categories.
Strengthened use of intelligence to identify and mitigate upstream supply chain risks.

Current situation

The evolving situation continues to present a potential risk to suppliers with facilities or dependencies in the region, including those linked to petrochemical-based materials used in essential healthcare products.

There is also an ongoing cost risk, both through core commodity pricing and indirect impacts on components and materials.

Shipping route disruption update

Security threats in the Red Sea and Bab el-Mandeb Strait continue to affect a major global shipping route. The Suez Canal typically carries around 12-15% of global trade and approximately 30% of container traffic between Asia and Europe.

Many shipping carriers have rerouted vessels around the Cape of Good Hope, resulting in longer transit times and increased transport costs.

Potential impacts include:

Extended lead times.
Reduced supply chain predictability.
Increased freight and insurance costs.
Additional pressure on petrochemical-based raw material prices.
Potential shortages in some product categories.

Products sourced from Asia, particularly where there are limited UK or European manufacturing alternatives, may experience longer lead times and increased costs. This could affect some medical consumables, PPE and diagnostic products.

While disruption continues to affect international shipping networks, products are continuing to move through the supply chain. At this stage, the most likely impact remains increased costs rather than significant disruption to product availability.

Enhanced actions and new measures

A coordinated and intelligence-led response remains in place across supply chain, resilience and category teams.

Targeted supplier engagement

Supply chain intelligence continues to inform a focused review of suppliers with upstream exposure to the Middle East.
Identified suppliers are being engaged directly, with ongoing assurances sought regarding continuity plans, logistics routes and any emerging constraints.

Product risk monitoring and mitigation

To mitigate this risk, a Middle East product risk watchlist is being implemented to identify and track affected products. This uses product, sourcing and inventory data to assess country of origin, material composition and risk level.

This approach enables teams to:

Prioritise monitoring of at-risk products.
Strengthen stock oversight through targeted stock alerts.
Rapidly identify alternative products.

This supports early intervention and continuity of supply.

Cyber risk assurance

Risk analytics are being used to monitor suppliers with elevated cyber-risk profiles.
Engagement with these suppliers is ongoing to confirm appropriate cyber protection measures are in place and to ensure there is no risk to NHS systems or supply continuity.

Horizon scanning and early warning

Teams continue to carry out horizon scanning to identify early indicators of disruption, including transport route instability and cyber threat activity.
Insights are shared across operational teams to support rapid decision-making and prioritisation.

Commodity forecasting and stock management

Commodity-level forecasting continues to identify products of potential concern and anticipate possible shortages.
Where appropriate, stockholding has been increased to strengthen resilience and maintain continuity of supply.

Intelligence-led disruption management

This model is strengthening NHS Supply Chain’s ability to anticipate and manage disruption across its global network:

Accelerated geopolitical response: Following escalation in the Middle East, 14 countries were geofenced, identifying 33 suppliers with Tier 1 or Tier 2 exposure. Targeted engagement replaced broad outreach, enabling rapid assessment of transport risks and mitigation actions.
Disruption containment: A sterilisation plant failure revealed dependencies across multiple Tier 1 suppliers. Early action prevented wider disruption.
Strategic sourcing: Tier 2 and Tier 3 risk visibility is informing sourcing decisions, supporting diversification and reducing concentration risk before contract award.

Ongoing position

We continue to work closely with suppliers and system partners to ensure a coordinated and effective response. Our priority remains ensuring a continuous supply to the NHS and protecting patient care.

Our approach will continue to evolve as we strengthen insight, improve risk visibility and respond to emerging supply chain challenges.

This article was first published in early April and has been regularly updated.